DLX-2201

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameDLX-2201

Drug Alias Nameanti-IL-12/23 antibody fragment (Delenex)therapeutic antibody fragments (Delenex Therapeutics)anti-IL-12/23 antibody fragment (Delenex)DLX-2201

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment

Mechanisms of ActionInterleukin-23 inhibitorsInterleukin-12 receptor inhibitors

TargetsInterleukin-12 receptorInterleukin-23

Therapy Area/IndicationsSkin DiseasesInflammatory Bowel Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwitzerland

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesCell Medica Switzerland AG

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCell Medica Switzerland AG

Active IndicationsN/A

Inactive IndicationsSkin DiseasesInflammatory Bowel Diseases

Other Information

ATC CodeN/A